CRANBURY, N.J., May 15, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced financial results for its fiscal third quarter ended March 31, 2024.
"Study results of our successful Phase 3 MELODY-1 clinical trial for DED demonstrate that PL9643, with its early onset of efficacy for multiple symptoms and signs of dry eye disease and the excellent ocular safety and tolerability profile, has the potential to be a highly differentiated product," said Carl Spana, Ph.D., President and Chief Executive Officer of Palatin. "The efficacy results were statistically significant for the co-primary symptom endpoint of pain and 7 of 11 exploratory secondary endpoints, including eye dryness, as early as two weeks, which was the first time point measured. We are advancing discussions with potential collaboration partners and actively preparing for a meeting with the FDA later this year to discuss the remaining studies for the PL9643 program required to support an NDA submission."
Dr. Spana further commented, "We are excited to launch two new therapeutic area clinical trials in the second quarter of calendar year 2024, with topline data readouts in the second half of calendar year 2024. The first is a Phase 2 clinical study of a MCR4 agonist plus a GLP-1 in obese patients. The second is a Phase 2 clinical study evaluating bremelanotide co-formulated with a PDE5i, for the treatment of erectile dysfunction in patients that do not respond to PDE5i monotherapy."
Fiscal Third Quarter Ended March 31, 2024 Business Highlights and Recent Updates
Anti-Inflammatory / Autoimmune Programs (melanocortin receptor agonists)
Metabolic Program (Obesity):
Male Sexual Dysfunction Program:
Other:
Fiscal Third Quarter Ended March 31, 2024 Financial Results
Revenue
Total revenue consists of gross product sales of Vyleesi, net of allowances and accruals.
Pursuant to the completion of the sale of Vyleesi's worldwide rights for female sexual dysfunction to Cosette Pharmaceuticals for up to $171 million in December 2023, Palatin did not record any product sales to pharmacy distributors for the quarter ended March 31, 2024. For the quarter ended March 31, 2023, gross product sales were $3.4 million, with net product revenue of $1.2 million.
Operating Expenses
Total operating expenses were $9.2 million compared to $8.5 million for the comparable quarter last year. The increase was related to greater spending on our MCR programs, offset partially by the elimination of selling expenses related to Vyleesi.
Other Income / (Expense)
Total other income / (expense), net, consists mainly of the change in fair value of warrant liabilities, which Palatin had recorded as a liability on the consolidated financial statements, including the revisions of certain prior period amounts to correct a misstatement with respect to classifying warrants as equity instead of a liability. The statement of operations was adjusted each quarter to reflect changes in the fair value of these warrants. For the quarters ended March 31, 2024, and 2023, Palatin recorded a fair value adjustment gain of $0.4 million and a loss of $1.5 million, respectively.
Warrant Liabilities
Palatin had assessed the impact of improperly classifying the warrants related to the October 2022 financing within equity, rather than as a warrant liability that is adjusted through charges or credits to the statement of operations to reflect changes in the fair value of the warrants, and determined the impact was not material to any prior period impacted. Accordingly, the Company adjusted prior periods as those financial statements are presented for comparative purposes in future filings.
On January 24, 2024, the Company and warrant holders amended the terms of the warrants related to the October 2022 and October 2023 financings. As a result, the $1.9 million of warrant liabilities as of June 30, 2023, was reclassified to additional paid-in capital upon amendment.
Cash Flows
Palatin's net cash used in operations was $8.6 million, compared to net cash used in operations of $1.4 million for the same period last year. The increase is mainly due to changes in working capital.
Net Loss
Palatin's net loss was $8.4 million, or $(0.53) per common share, compared to a net loss of $8.7 million, or $(0.76) per common share for the comparable period last year.
The decrease over the comparable quarter last year was mainly due to a larger operating loss in fiscal 2024 offset by the higher other income primarily from changes in the fair value of warrant liabilities.
Cash Position
As of March 31, 2024, Palatin's cash, cash equivalents and marketable securities were $10.0 million, compared to cash, cash equivalents and marketable securities of $9.5 million plus $2.3 million of accounts receivable, as of December 31, 2023, and $5.5 million plus $1.3 million of accounts receivable, as of September 30, 2023, and cash, cash equivalents and marketable securities of $11.0 million plus $2.9 million of accounts receivable, as of June 30, 2023.
The Company believes that existing cash, cash equivalents, marketable securities and accounts receivable, will be sufficient to fund currently anticipated operating expenses and disbursements into the second half of calendar year 2024.
Conference Call / Webcast
Palatin will host a conference call and audio webcast on May 15, 2024, at 11:00 a.m. Eastern Time to discuss the results of operations in greater detail and provide an update on corporate developments. Individuals interested in listening to the conference call live can dial 1-877-545-0523 (US) or 1-973-528-0016 (International), conference ID 720217. The audio webcast and replay can be accessed by logging on to the "Investor-Webcasts" section of Palatin's website at http://www.palatin.com or by clicking here. A telephone and audio webcast replay will be available one hour after the completion of the call. To access the telephone replay, dial 1-877-481-4010 (US) or 1-919-882-2331 (International), passcode 50601. The webcast and telephone replay will be available through May 29, 2024.
About Melanocortin Receptor Agonists
The melanocortin receptor ("MCR") system has effects on inflammation, immune system responses, metabolism, food intake, and sexual function. There are five melanocortin receptors, MCR1 through MCR5. Modulation of these receptors, through use of receptor-specific agonists, which activate receptor function, or receptor-specific antagonists, which block receptor function, can have medically significant pharmacological effects.
Many tissues and immune cells located in the eye (and other places, for example the gut and kidney) express melanocortin receptors, empowering our opportunity to directly activate natural pathways to resolve disease inflammation.
About Palatin
Palatin is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin's website at www.Palatin.com and follow Palatin on Twitter at @PalatinTech.
Forward-looking Statements
Statements in this press release that are not historical facts, including statements about future expectations of Palatin Technologies, Inc., such as statements about Palatin products in development, clinical trial results, potential actions by regulatory agencies including the FDA, regulatory plans, development programs, proposed indications for product candidates, and market potential for product candidates are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause Palatin's actual results to be materially different from its historical results or from any results expressed or implied by such forward-looking statements. Palatin's actual results may differ materially from those discussed in the forward-looking statements for reasons including, but not limited to, results of clinical trials, regulatory actions by the FDA and other regulatory and the need for regulatory approvals, Palatin's ability to fund development of its technology and establish and successfully complete clinical trials, the length of time and cost required to complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin's products, and other factors discussed in Palatin's periodic filings with the Securities and Exchange Commission. Palatin is not responsible for updating events that occur after the date of this press release.
Palatin Technologies® is a registered trademark of Palatin Technologies, Inc.
(Financial Statement Data Follows)
PALATIN TECHNOLOGIES, INC. | |||||||
and Subsidiary | |||||||
Consolidated Statements of Operations | |||||||
(unaudited) | |||||||
Three Months Ended March 31, | Nine Months Ended March 31, | ||||||
2024 | 2023 | 2024 | 2023 | ||||
REVENUES | |||||||
Product revenue, net | $ - | $ 1,195,675 | $ 4,140,090 | $ 3,091,745 | |||
OPERATING EXPENSES | |||||||
Cost of products sold | - | 129,235 | 97,637 | 314,438 | |||
Research and development | 7,159,686 | 4,830,327 | 17,728,516 | 15,224,896 | |||
Selling, general and administrative | 2,033,410 | 3,537,376 | 8,266,267 | 10,220,518 | |||
Gain on sale of Vyleesi | 25,202 | - | (7,798,280) | - | |||
Gain on purchase commitment | - | - | - | (1,027,322) | |||
Total operating expenses | 9,218,298 | 8,496,938 | 18,294,140 | 24,732,530 | |||
Loss from operations | (9,218,298) | (7,301,263) | (14,154,050) | (21,640,785) | |||
OTHER INCOME (EXPENSE) | |||||||
Investment income | 139,273 | 234,044 | 272,929 | 509,006 | |||
Foreign currency gain (loss) | 215,600 | (77,266) | 68,653 | (352,121) | |||
Interest expense | (1,254) | (3,434) | (13,741) | (18,525) | |||
Offering expenses | - | - | (696,912) | (1,115,765) | |||
Change in fair value of warrant liabilities | 429,029 | (1,521,413) | (6,962,562) | 3,725,895 | |||
Total other income (expense) income, net | 782,648 | (1,368,069) | (7,331,633) | 2,748,490 | |||
(Loss) before income taxes | (8,435,650) | (8,669,332) | (21,485,683) | (18,892,295) | |||
Income tax benefit | - | - | - | 4,674,999 | |||
NET (LOSS) INCOME | $ (8,435,650) | $ (8,669,332) | $ (21,485,683) | $ (14,217,296) | |||
Basic and diluted net loss per common share | $ (0.53) | $ (0.76) | $ (1.53) | $ (1.34) | |||
Weighted average number of common shares outstanding used in computing basic and diluted net loss per common share | 15,792,421 | 11,432,380 | 14,013,848 | 10,613,830 | |||
PALATIN TECHNOLOGIES, INC. | |||
and Subsidiary | |||
Consolidated Balance Sheets | |||
(unaudited) | |||
March 31, 2024 | June 30, 2023 | ||
ASSETS | |||
Current assets: | |||
Cash and cash equivalents | $ 10,014,088 | $ 7,989,582 | |
Marketable securities | - | 2,992,890 | |
Accounts receivable | - | 2,915,760 | |
Inventories | - | 526,000 | |
Prepaid expenses and other current assets | 254,554 | 1,897,281 | |
Total current assets | 10,268,642 | 16,321,513 | |
Property and equipment, net | 465,410 | 684,910 | |
Right-of-use assets - operating leases | 615,269 | 876,101 | |
Other assets | 56,916 | 56,916 | |
Total assets | $ 11,406,237 | $ 17,939,440 | |
LIABILITIES AND STOCKHOLDERS' DEFICIENCY | |||
Current liabilities: | |||
Accounts payable | $ 3,443,247 | $ 4,303,527 | |
Accrued expenses | 2,364,964 | 6,511,059 | |
Short-term operating lease liabilities | 371,280 | 354,052 | |
Short-term finance lease liabilities | 73,141 | 106,392 | |
Other current liabilities | 2,280,150 | 3,856,800 | |
Total current liabilities | 8,532,782 | 15,131,830 | |
Long-term operating lease liabilities | 262,220 | 544,323 | |
Long-term finance lease liabilities | - | 46,014 | |
Other long-term liabilities | 1,032,300 | 2,083,200 | |
Warrant liabilities | - | 1,850,544 | |
Total liabilities | 9,827,302 | 19,655,911 | |
Contingently redeemable warrants | - | 263,400 | |
Stockholders' deficiency: | |||
Preferred stock of $0.01 par value – authorized 10,000,000 shares: shares issued | |||
and outstanding designated as follows: | |||
Series A Convertible: authorized 4,030 shares as of March 31, 2024: issued and | |||
outstanding 4,030 shares as of March 31, 2024 and June 30, 2023 | 40 | 40 | |
Common stock of $0.01 par value – authorized 300,000,000 shares: | |||
issued and outstanding 16,136,640 shares as of March 31, 2024 and 11,656,714 shares as of June 30, 2023 | 161,366 | 116,567 | |
Additional paid-in capital | 434,933,649 | 409,933,959 | |
Accumulated deficit | (433,516,120) | (412,030,437) | |
Total stockholders' equity (deficiency) | 1,578,935 | (1,979,871) | |
Total liabilities and stockholders' equity (deficiency) | $ 11,406,237 | $ 17,939,440 | |
| Last Trade: | US$1.11 |
| Daily Volume: | 439,197 |
| Market Cap: | US$26.040M |
December 19, 2024 December 16, 2024 November 25, 2024 November 14, 2024 November 04, 2024 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
